Skip to the reporting
My account Sign in Subscribe
2 of 3 free articles left this month Subscribe now
← Funding
Funding Funding

Oxford spin-off Zya raises £12m to bring a sugar-to-fibre enzyme to American snacks

Astanor leads the Series A as the London start-up heads into human trials and a US safety review for Convero, and pushes its planned launch back to the…

By Zack Hill November 16, 2026 · 4 min read
Share Share on X Share on LinkedIn Share on Facebook Share on WhatsApp Email this

Astanor leads the Series A as the London start-up heads into human trials and a US safety review for Convero, and pushes its planned launch back to the end of 2027.

Zya, a London food-technology company started by two Oxford biochemists, has raised £12 million in a Series A round. The money will take its first ingredient through human studies and US regulatory review. The ingredient is an enzyme meant to turn part of the sugar in a food into fibre after the food is eaten.

Astanor, the Brussels-based agrifood investor, led the round. Ahren Innovation Capital, Red Bull Ventures, Zubi Capital, Phase Change and Meach Cove Capital also took part. Zya said the funds would pay for clinical and regulatory work and for commercial partnerships, with the aim of launching the ingredient, Convero, with food manufacturers in the United States by the end of 2027.

The company is selling a way round reformulation, a problem food makers have struggled with for years. Sugar adds bulk, texture and browning as well as sweetness, and replacing it usually changes how a product tastes or how it behaves on the production line. Convero is sold as a dry powder and added to an existing recipe. Zya says the enzyme stays inactive in the product and goes to work only during digestion, converting about 30% of the sugar into fructooligosaccharides (FOS), a prebiotic fibre that feeds gut bacteria.

“Sugar is one of the hardest problems in food,” said Joshua Sauer, Zya’s co-founder and chief executive. “You can’t simply remove it without changing everything people love about a product.”

Christina Ulardic, a partner at Astanor, said nearly every sugar-reduction approach the firm had looked at changed the taste or functionality of the finished product. Astanor already knew the company: it was one of the backers of Zya’s 2023 pre-seed round, alongside Better Ventures, Exor, Exerte Partners and Great Circle Ventures.

The main claim has not yet been shown in people, and that is what much of the new money is for. When Zya came out of stealth in early 2024, it reported results from laboratory work only. In models of the human gut, the enzyme converted up to 30 percent of the sugar present into fibre, and the company also fed enzyme-treated food to pigs, whose digestive tracts resemble ours. Its safety toxicology programme has since been published in the journal Toxicology Reports. Zya has not released human efficacy data.

The regulatory route is also changing. Zya is pursuing a self-affirmed GRAS (Generally Recognized As Safe) determination, expected by the end of this year, and plans a formal submission to the Food and Drug Administration afterwards. Under the self-affirmed route, a company relies on its own panel of experts to conclude that an ingredient is safe for its intended use, without the FDA reviewing it first. That route is now under review. On August 11, the Department of Health and Human Services published a proposed rule that would require companies to notify the FDA when they conclude that an ingredient is generally recognised as safe. Public comments are due by December 9. The proposal grew out of a directive from Robert F. Kennedy Jr., the health secretary, who in March 2025 told the FDA to explore eliminating the self-affirmed pathway entirely. Because Zya had already planned to file with the agency, the proposal may change its timetable less than it would for companies that relied on self-affirmation alone.

The launch date has already slipped once. When Convero was unveiled, the company was targeting a US launch in 2026, pending FDA approval.

On the commercial side, Zya says it has finished feasibility projects with multinational food companies, several of which are moving towards co-development, and that more than 100 companies are in its sales pipeline. It is starting with low-moisture products: chocolate, cereal bars, biscuits and confectionery. According to CB Insights, the pladis Accelerator Programme invested in Zya in July 2025. Pladis owns McVitie’s and Godiva biscuits.

Sauer and Niels Wicke, the company’s chief scientific officer, founded Zya in 2018 while studying for doctorates at Oxford. The business traded as Inulox before taking its current name. Its earliest descriptions of the technology centred on an enhanced version of inulosucrase, an enzyme that converts sucrose into inulin fibre. The company now describes the fibre it produces as FOS, a shorter-chain relative of inulin. Convero is made by precision fermentation.

Others are working on the same idea. Israel’s Better Juice uses enzymes to change sugars in sweet beverages into dietary fibres and other non-digestible sugars. Researchers at Harvard’s Wyss Institute, working with Kraft Heinz, have encapsulated a sugar-converting plant enzyme in an edible coating that keeps it inactive on the shelf and releases it in the intestine.

Zya’s next milestone is the GRAS determination it expects in the coming weeks. The more important one is the result of its first human studies, which will show whether conversion seen in laboratory models and pigs also happens in the human gut.

The Daily Briefing
One email, 7am, the six things that moved

Written by the newsroom, not a summariser. Free, and you can leave whenever.

0 comments

Anyone can read the thread · subscribers can post
Subscriber conversation Read the thread below as long as you like. Posting is open to subscribers, which is why it reads like a newsroom and not a comment section. Join the conversation Sign in
Sponsored Paid for by the advertiser. The newsroom had no part in it.

More on this topic

All Funding →